★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Vertex Pharmaceuticals Incorporated (VRTX) Moat Analysis
Vertex Pharmaceuticals Incorporated
VRTX · The Nasdaq Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Vertex is a U.S. biotechnology company focused on specialty medicines. In Q2 2026, CF medicines generated 96.2% of product revenue; the franchise's durable barrier is a deep Orange Book patent estate with basic product protection extending to 2037 for TRIKAFTA/KAFTRIO and 2039 for ALYFTREK. CASGEVY contributed 2.3% and adds 12-year U.S. biologic exclusivity plus product/manufacturing IP; the July 2026 U.S. label expansion to age two and older added about 5,500 eligible children. JOURNAVX contributed 1.5% and has a basic product patent through 2040, but launch uptake and payer access are commercial progress rather than separate moats. The three product categories are analytical, not separately reported operating segments, so no product-level operating-profit allocation is available.
Primary segment
Cystic Fibrosis CFTR Modulators
Market structure
Quasi-Monopoly
Market share
72%-75% (reported)
HHI: —
Coverage
3 segments · 5 tags
Updated 2026-08-23
Segments
Cystic Fibrosis CFTR Modulators
CFTR modulator therapies for cystic fibrosis
Revenue
96.2%
Structure
Quasi-Monopoly
Pricing
strong
Share
72%-75% (reported)
Peers
Hemoglobinopathies Gene Therapy (CASGEVY)
Gene-editing / gene therapy for sickle cell disease and transfusion-dependent beta thalassemia
Revenue
2.3%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Acute Pain (JOURNAVX)
Moderate-to-severe acute pain pharmacotherapy (non-opioid analgesics)
Revenue
1.5%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Cystic Fibrosis CFTR Modulators
CFTR modulator therapies for cystic fibrosis
Analytical product category within Vertex's consolidated operations; the filing does not allocate operating profit by product. Revenue share is Q2 2026 CF product revenue of $3.2079B divided by $3.3339B total product revenue. Vertex estimates its CF medicines are used by nearly three quarters of about 97,000 people with CF in the U.S., Europe, Australia and Canada.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Large Orange Book-listed patent estate plus regulatory exclusivity supports long-lived protection for CFTR modulators (including TRIKAFTA/KAFTRIO and ALYFTREK).
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges / invalidation
- Post-expiry generic entry after late-2030s
- Breakthrough non-modulator modalities (gene therapy, mRNA) reducing modulator demand
Leading indicators
- Orange Book litigation / Paragraph IV filings
- Competitor CF genetic therapy clinical milestones
- Net realized pricing trend and payer restriction rates
Counterarguments
- High pricing makes CF payers highly motivated to support cheaper alternatives when available
- A truly curative CF genetic therapy could bypass CFTR modulators entirely
Long Term Contracts
Demand
Long Term Contracts
Strength
Durability
Confidence
Evidence
An extended long-term NHS England reimbursement agreement provides contracted access for the established CF portfolio, while remaining non-exclusive and exposed to payer renegotiation.
Long Term Contracts moat: definition, examples, and stocks
Erosion risks
- National payers renegotiate pricing or access terms
- Credible competing therapies weaken renewal economics
- Policy-driven price reductions lower contract value
Leading indicators
- National reimbursement renewals and amendments
- Net realized pricing
- Competitor reimbursement decisions
Counterarguments
- The agreement is not exclusive and payer bargaining power remains substantial.
Hemoglobinopathies Gene Therapy (CASGEVY)
Gene-editing / gene therapy for sickle cell disease and transfusion-dependent beta thalassemia
Analytical product category within Vertex's consolidated operations; the filing does not allocate operating profit by product. Revenue share is Q2 2026 CASGEVY revenue of $76.4M divided by $3.3339B total product revenue. Vertex leads commercialization under the CRISPR collaboration and shares 40% of net commercial profit or loss with CRISPR Therapeutics.
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
BLA pathway provides multi-year regulatory exclusivity; CASGEVY also benefits from orphan-style barriers (specialized centers, conditioning regimens).
Regulated Standards Pipe moat: definition, examples, and stocks
Erosion risks
- Competing gene therapies / gene editing with better safety, simpler conditioning, or lower total cost
- Regulatory changes for cell/gene therapy manufacturing and patient support
Leading indicators
- Number of authorized treatment centers activated
- Patient cell collection / infusion run-rate
- Competitor approvals and label expansions
Counterarguments
- First-to-market advantage may be limited if competitors scale faster or offer easier logistics
- Long-term safety data are still accruing, potentially constraining uptake
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patent and know-how protection on gene-editing constructs and manufacturing processes can raise freedom-to-operate barriers, but CRISPR IP is complex and litigated.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- IP litigation outcomes weakening protection
- Alternative editing modalities (base/prime editing) avoiding key patents
Leading indicators
- Patent litigation filings/settlements related to CRISPR editing
- Competitor platform shifts to non-infringing approaches
Counterarguments
- CRISPR IP landscape is fragmented, making durable exclusion difficult
- Clinical execution and logistics may matter more than patents for near-term share
Acute Pain (JOURNAVX)
Moderate-to-severe acute pain pharmacotherapy (non-opioid analgesics)
Analytical product category within Vertex's consolidated operations; the filing does not allocate operating profit by product. Revenue share is Q2 2026 JOURNAVX revenue of $49.6M divided by $3.3339B total product revenue. About 535,000 prescriptions were filled in Q2, 23 states provided Medicaid coverage and about 260M people had reimbursed access, but analgesics competition remains intense.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patent protection, Orange Book listing and long basic patent life support branded exclusivity, but large-market incentives attract challengers.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Paragraph IV challenges once listed
- Safety signals limiting broad use
Leading indicators
- Patent listings and challenges
- Adverse event reporting and label changes
Counterarguments
- Analgesics are heavily commoditized; patents may not prevent rapid payer substitution
- Competitors could launch differentiated non-opioid mechanisms
Evidence
We have 34 issued U.S. patents listed in the Orange Book
Shows the listed patent estate around TRIKAFTA/KAFTRIO.
We have 35 issued U.S. patents listed in the Orange Book
Shows the listed patent estate around ALYFTREK.
TRIKAFTA/KAFTRIO ... basic product patent ... 2037; ALYFTREK ... 2039.
Basic patent expirations extend into the late 2030s (before any extensions/secondary patents).
entered into an extended long-term reimbursement agreement with NHS England providing access to KAFTRIO, SYMKEVI and ORKAMBI
Directly establishes long-term contractual payer access for the CF franchise.
being used by nearly three quarters of the approximately 97,000 people with CF
Direct management disclosure of treated-patient penetration.
Showing 5 of 11 sources.
Risks & Indicators
Erosion risks
- Patent challenges / invalidation
- Post-expiry generic entry after late-2030s
- Breakthrough non-modulator modalities (gene therapy, mRNA) reducing modulator demand
- National payers renegotiate pricing or access terms
- Credible competing therapies weaken renewal economics
- Policy-driven price reductions lower contract value
Leading indicators
- Orange Book litigation / Paragraph IV filings
- Competitor CF genetic therapy clinical milestones
- Net realized pricing trend and payer restriction rates
- National reimbursement renewals and amendments
- Net realized pricing
- Competitor reimbursement decisions
Research VRTX elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.